

Special Issue

Neuropathic Pain: Therapy and Mechanisms

Message from the Guest Editors

Neuropathic pain, known to be originating from abnormal or damaged nerves, often manifests as shooting or burning pain. It is especially burdensome when it turns chronic, negatively impacting the well-being of patients, their social relationships, daily activities, as well as work productivity. The use of opioids for the management of chronic pain has received significant attention in the recent decade, and several additional pharmacological and non-pharmacological treatments have been developed and approved for chronic pain management. This Special Issue on neuropathic pain intends to present the progress in the treatment of chronic pain and highlight the current understanding of pathophysiological and biochemical pathways involved in neuropathic pain. All article types related to neuropathic pain, pathophysiology, treatment (pharmacological as well as non-pharmacological), and biomarkers are considered within the scope of this Special Issue.

Guest Editors

Dr. Anand Rotte

Clinical and Regulatory Affairs, Arcellx, Gaithersburg, MD, USA

Prof. Sam Eldabe

Honorary Professor, Warwick University; Consultant, South Tees Hospitals NHS Foundation Trust, Middlesbrough, UK

Deadline for manuscript submissions

closed (31 July 2021)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/63339

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).